Retatrutide TRIUMPH Trials 2026: What the Phase 3 Data Means for the GLP Industry

Eli Lilly's retatrutide — a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously — has produced some of the most impressive weight loss data ever seen in a pharmaceutical trial. With Phase 3 TRIUMPH data now available, the implications for the GLP industry, for clinics, and for patients are significant.

Retatrutide is a once-weekly injectable peptide that activates three receptors:

• GLP-1 receptor: Appetite suppression, slowed gastric emptying, glucose-dependent insulin secretion
• GIP receptor: Enhanced insulin secretion, direct adipose tissue effects (as with tirzepatide)
• Glucagon receptor: Increased energy expenditure, enhanced fat oxidation, reduced hepatic fat

The addition of glucagon receptor agonism to the GLP-1/GIP dual mechanism is the key differentiator. Glucagon increases basal metabolic rate and promotes fat burning — effects that complement the appetite suppression of GLP-1 and the metabolic benefits of GIP.

The flagship obesity trial enrolled adults with BMI ≥30 (or ≥27 with weight-related comorbidity) without type 2 diabetes.

Results at 80 weeks:

• Retatrutide 12 mg: 28.8% average weight loss
• Retatrutide 8 mg: 24.1% average weight loss
• Placebo: 2.1% weight loss

For context: semaglutide 2.4 mg produces approximately 15% weight loss; tirzepatide 15 mg produces approximately 22.5% weight loss. Retatrutide's 28.8% represents a meaningful step forward.

Responder rates:

• ≥20% weight loss: 73% of patients on 12 mg
• ≥25% weight loss: 57% of patients on 12 mg
• ≥30% weight loss: 38% of patients on 12 mg

In patients with T2D, retatrutide produced:

• 17.5% average weight loss (12 mg dose)
• HbA1c reduction of 2.4% — among the largest reductions seen with any non-insulin agent
• Significant improvements in lipids, blood pressure, and liver enzymes

The cardiovascular outcomes trial is ongoing. Given the magnitude of weight loss and metabolic improvements, significant cardiovascular risk reduction is anticipated — but the data is not yet available.

The glucagon receptor component is what separates retatrutide from tirzepatide. Glucagon:

• Increases basal metabolic rate (burns more calories at rest)
• Promotes fat oxidation (preferential fat burning)
• Reduces hepatic fat accumulation
• May preserve lean muscle mass better than GLP-1 alone

This is why retatrutide produces greater weight loss than tirzepatide despite similar GLP-1 and GIP components — the glucagon receptor adds a third mechanism that amplifies the metabolic effect.

One concern with aggressive weight loss is muscle loss. Early data from the TRIUMPH trials suggests retatrutide may preserve lean mass better than semaglutide, potentially due to the glucagon receptor's effects on protein metabolism. Full body composition data is expected with the complete trial publication.

Retatrutide sets a new efficacy benchmark for obesity pharmacotherapy. The 28.8% average weight loss approaches the weight loss seen with bariatric surgery (typically 25–35% of body weight). This raises the question: for some patients, could pharmacotherapy replace surgery?

Retatrutide's superior efficacy will create competitive pressure on tirzepatide (Zepbound/Mounjaro) and semaglutide (Wegovy/Ozempic). Patients who do not achieve adequate response to tirzepatide will have a compelling next-line option.

For clinics interested in participating in the retatrutide research ecosystem, IRB-supported research protocols offer a pathway to access retatrutide in a compliant research context. MedClinic Partners facilitates IRB enrollment for practices interested in this pathway.

Retatrutide is not yet FDA-approved, but it is available as a compounded preparation through 503A pharmacies for patient-specific prescriptions. Practices that want to offer retatrutide to patients who have not achieved adequate response to tirzepatide can do so through our portal.

Request portal access →

This content is for informational and educational purposes only. Retatrutide is not FDA-approved. It does not constitute medical advice. Prescribers should use clinical judgment.